Related Experiment Video
Updated: Jun 9, 2026

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
Published on: May 23, 2025
Protein Engineering to Change the Sugar Donor and Improve the Activity of PnUGT94Q39 for Efficient Ginsenoside Rf
Maoqi Hou1, Sijie Chen1, Li Yang1,2
1State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, The SATCM Key Laboratory for New Resources & Quality Evaluation of Chinese Medicine, The MOE Key Laboratory for Standardization of Chinese Medicines and Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P. R. China.
Abstract:
Ginsenoside Rf, a rare protopanaxatriol-type ginsenoside derived from Panax ginseng, exhibits notable neuroprotective, anti-inflammatory, and antitumor properties. However, its low natural abundance has impeded large-scale production. Here, we reprogrammed the sugar donor specificity of PnUGT94Q39 from UDP-xylose to UDP-glucose, thereby enabling efficient ginsenoside Rf biosynthesis. A single-point mutation (I142T) within a flexible loop not only switched the sugar donor preference to UDP-glucose but also established efficient catalysis (kcat/Km, 1.18 μM-1·min-1) toward this donor. Coupling the I142T mutant with sucrose synthase GmSUS in Escherichia coli enabled the production of ginsenoside Rf (Rf) from ginsenoside Rh1 (Rh1) without exogenous UDP-glucose addition. Under optimized whole-cell biocatalysis conditions, a ginsenoside Rf titer of 1219.49 mg·L-1 was achieved, corresponding to a 97.26% conversion rate from Rh1 to Rf. Collectively, this work generated an efficient PnUGT94Q39-I142T mutant and established a sustainable, high-efficiency route for ginsenoside Rf production.
Related Concept Videos
Production of Pharmaceuticals
Bioreactor Controls-III

